Table 1 Demographic data and clinical characteristics of participants

From: Elevated peripheral expression of neuregulin-1 (NRG1) mRNA isoforms in clozapine-treated schizophrenia patients

Characteristic

Schizophrenia (n = 71)

Controls (n = 57)

P-value

Age, mean (sd) years

40 (10)

40 (11)

0.702a

Gender, n (%) males

53 (75)

35 (61)

0.108b

RNA integrity number, mean (sd)

8.4 (0.9)

8.7 (0.3)

0.006a*

Ancestry, n (%) CEU

62 (90)

50 (88)

0.742b

Substance use in past three months, n (%)

   

 Tobacco (smoked)

33 (47)

12 (21)

0.003b*

 Alcohol

59 (83)

55 (97)

0.016b*

 Cannabis

11 (15)

7 (12)

0.385b

 Amphetamine

4 (6)

2 (4)

0.439b

 Cocaine

0 (0)

2 (4)

0.137b

 Opiates

1 (1)

1 (2)

0.990b

Clozapine plasma level, mean (sd) µg/L

432 (234)

—

—

Chlorpromazine equivalent (excluding clozapine) dosage mean (sd) mg/day

142 (286)

—

—

Age of onset, mean (sd) years

22.5 (6)

—

—

Duration of illness, mean (sd) years

17 (8)

—

—

PANSS scores, mean (sd)

   

 Positive

10 (6)

—

—

 Negative

15 (5)

—

—

 Disorganized

8 (3)

—

—

 Excitement

6 (2)

—

—

 Depression

6 (3)

—

—

 Total

62 (14)

—

—

  1. CEU Northern and Western European ancestry, TRS treatment-resistant schizophrenia, RIN RNA integrity number, PANSS Positive and Negative Syndrome Scale, mg milligram
  2. aIndependent sample t-test
  3. bChi-square(χ 2) test
  4. *P < 0.05
Back to article page